Primary Ciliary Dyskinesia
Conditions
Keywords
primary ciliary dyskinesia, respiratory physiotherapy, airway clearance techniques, lung function testing, ventilation inhomogeneity, nitrogen multiple breath washout test, spirometry, electric impedance tomography
Brief summary
Primary ciliary dyskinesia (PCD) is characterized by impaired airway clearance and mucus stagnation. This results in recurrent upper and lower respiratory tract infections often leading to chronic inflammation and, if not treated early and properly, to irreversible functional and structural changes of the respiratory tract. As there is no causal treatment of PCD yet, airway clearance techniques (ACT) provide fundamental care for these patients. Simeox is a new airway clearance device, recently developed by the French company PhysioAssist. This technology is based on pneumatic vibrations generated by the device itself. Vibrations are induced by rapidly alternating between atmospheric and negative pressure as the patient exhales, providing the most effective clearance of mucus from the lungs. Vibrations of different intensity and frequency are known to alter the rheological properties of mucus in the airways, whilst the negative pressure during exhalation helps to mobilise and drain the mucus to the central bronchi. Although there have not yet been any evidence based papers published clarifying the effect of Simeox specifically in patients with PCD, using up-to-date information, experience, and positive feedback from our patients, we assume that there could be a significant benefit for the effectiveness of ACT.
Detailed description
In this study the effectiveness of ACT will be evaluated based on the short-term effect(s) of respiratory physiotherapy with Simeox on changes in lung function and thoracic expansibility paediatric patients with PCD. An interventional randomised non-inferiority crossover trial will be conducted in Motol University Hospital; the project was developed by the multidisciplinary team (MDT) of the Division of Paediatric Pulmonology of the Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital; and the Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital. Eligible patients will be randomly assigned into 2 arms - Simeox-first group and Pari-O-PEP first group. Randomisation will be done using computer generated code for each patient. The protocol will include 3 study visits - K0, K1 and K2 planned 3 months apart. After 6 months (second visit - K1), each patient will be switched to the other interventional group (crossed over). The first session (K0) includes an initial lung function assessment using spirometry, nitrogen-Multiple Breath Washout test (N2-MBW), Electrical Impedance Tomography (EIT), 6 Minute Walk Test (6 MWT), respiratory amplitudes (RA), and a theoretical introduction to therapy with the Simeox device. The second (K1) and third (K2) sessions will be interventional, including a respiratory physiotherapy session in between each measurement, excluding 6 MWT, which will be measured just once per session. According to randomisation criteria, participants will initially undergo either physiotherapist-administered 20-minute ACT session using the Simeox device or 30-minute therapy with PARI O-PEP. In accordance with the rules for crossover study design, each patient will undergo therapy with both ACT devices, ideally within six-month duration of the study. These interventions will take place in between each measurement (spirometry, MBW, EIT, RA) during the second (K1) and the third (K2) session.
Interventions
DEVICESimeox
A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are; * clearance of the upper airways before the physiotherapy session * correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece * slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax * step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs * comfortable, relaxed sitting position with straightened spine * controlled cough, which will be encouraged only when it is productive
DEVICEPARI O PEP
ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be: * horizontal; * low; * transition of the device from the low position to the horizontal position; * upside down. The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum.
Sponsors
University Hospital, Motol
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
First session - initial medical and physiotherapy assessment Second session - medical and physiotherapy assessment, respiratory physiotherapy with Simeox/PARI O PEP (according the randomization) Third session - medical and physiotherapy assessment, respiratory physiotherapy with Simeox/PARI O PEP (according the randomization)
Eligibility
Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of PCD confirmed by Transmission Electron Microscopy (TEM) analysis of ciliary ultrastructure showing clear structural axonemal defect and/or positive genetic testing for one (autosomal dominant) or two (autosomal recesive) PCD-causing mutations; * age range 4 - 18 years; * established chest physiotherapy with PARI O PEP
Exclusion criteria
* inability to undergo the assessment and intervention * noncompliance and/or nonadherence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Lung Clearance Index | Through study completion, an average of 1 year | Ventilation Inhomogenity Assesment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Forced Residual Capacity (FRC) | Through study completion, an average of 1 year | Volume of air present in the lungs at the end of passive expiration, in Litres \[L\]. |
| Change in Forced Vital Capacity (FVC) | Through study completion, an average of 1 year | Volume of air that can forcibly be blown out after full inspiration, in Litres \[L\] |
| Change in Forced Expiratory Volume in 1 second (FEV1) | Through study completion, an average of 1 year | Volume of air exhaled in the first second during forced exhalation after full inspiration, in Litres per second \[L/s\] |
| Change in Acinar airway inhomogeneity (Sacin) | Through study completion, an average of 1 year | MBW indices reflecting ventilation inhomogeneity in the acinar airway region, in Litres \[L\] |
| Change in Conductive airway inhomogeneity (Scond) | Through study completion, an average of 1 year | MBW indices reflecting ventilation inhomogeneity in the conductive airway region, in Litres \[L\] |
| Change in Maximal Expiratory Flow (MEF25-75) | Through study completion, an average of 1 year | Volume of air where the certain amount (25-75%) of Forced Vital Capacity (FVC) remains to be exhaled, in Litres \[L\] |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in Global Inhomogeneity (GI) Index | Through study completion, an average of 1 year | Electrical Impedance Tomography parameter evaluating real-time spatial distribution of ventilation |
| Change in chest expansion measurement | Through study completion, an average of 1 year | Chest expanson at axillary, mesosternal (mammary) and xiphosternal levels |
Countries
Czechia
Outcome results
None listed